80
Participants
Start Date
September 30, 2016
Primary Completion Date
September 6, 2022
Study Completion Date
September 6, 2022
BL-8040
BL-8040 subcutaneous (SC) injections
Pembrolizumab
Pembrolizumab will be given as a 30-minute IV infusion
Chemotherapy
• IV Onivyde® followed by IV leucovorin (LV), followed by IV fluorouracil (5-FU), every 2 weeks.
NYU Langone Health, New York
University of Rochester, Rochester
Gregorio Marañón Hospital, Madrid
Hospital Universitario de Fuenlabrada, Madrid
Karmanos Cancer Center, Wayne State University, Detroit
Washington University of St Louis, St Louis
Ochsner Medical Center, New Orleans
Baylor Charles A. Sammons Cancer Center, Dallas
Mayo Clinic, Phoenix
Honor Health, Scottsdale
Shaare Zedek Medical Center, Jerusalem
Virginia Mason Medical Center, Seattle
Massachusetts General Hospital (MGH), Boston
Beth Israel Deaconess Medical Center (BIDMAC), Boston
DF/HCC, Boston
Atlantic Medical Group, Morristown
Cornell Medical College, New York
Rambam Medical Center, Haifa
Rabin Medical Center, Petah Tikva
Chaim Sheba Medical Center, Ramat Gan
Sourasky Medical Center, Tel Aviv
Hospital General Universitario de Elche, Alicante
Hospital Universitario Ramón y Cajal, Madrid
La Paz, Madrid
Hospitalario Universitario de Ourense, Ourense
Clinic Universidad de Navarra, Pamplona
University Hospital of Salamanca, Salamanca
Marques de Valdecilla de Santander, Santander
Hospital Universitari i Politècnic La Fe,, Valencia
Samsung Medical Center, Seoul
Vall d'Hebron, Barcelona
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
BioLineRx, Ltd.
INDUSTRY